TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Bafna Pharmaceuticals Ltd
BAFNAPH Updated about 5 hours ago

Bafna Pharmaceuticals Ltd Share Price

NSE closing price and which mutual funds hold this stock

TopFund Score: 47/100 · Weak See breakdown ↓

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 25 Sep 2026

₹350.05

Change

+6.85 (2.0%)

Open

₹350.05

Prev. Close

₹343.2

Day High

₹350.05

Day Low

₹350.05

Volume Analysis

Traded

2,166

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Trading within 3% of its 52-week high (₹356.0)

Weaknesses (4)

  • •Low return on equity (-6.18%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (47/100)
  • •Low operating margin (2.9%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05
Fibonacci ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05
Camarilla ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05 ₹350.05

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+135.9%

1 Week

+8.21%

1 Month

+20.25%

3 Months

+63.09%

6 Months

+212.66%

1 Year

+98.52%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-46.86%

Net margin -57.14% × asset turnover 0.59x × equity multiplier 1.39x

Company Overview

Sector

Healthcare

Market Cap

₹842 Cr

ROE

-6.18%

Book Value

₹216.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Bafna Pharmaceuticals Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 47/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹356.0); low return on equity (-6.18%); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

47/100 — Weak

Data confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

50

Cash Flow

33

Corporate Governance

43

Momentum

100

Institutional Ownership

65

Business Quality

22

Risk & Volatility

67

Liquidity

0

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Debtor days have improved from 151 to 51.8 days.
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -15.2% over past five years.
  • −Company has a low return on equity of -63.9% over last 3 years.
  • −Working capital days have increased from -77.3 days to 90.4 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 11 Sep 11 Sep
Shareholder Meeting / Postal Ballot-Outcome of AGM 11 Sep

31st AGM held on 11 September 2026; audited accounts adopted, director reappointed, cost auditor remuneration ratified.

Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Aug

We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, …

Reg. 34 (1) Annual Report. 19 Aug

FY26 annual report filed; 31st AGM scheduled for September 11, 2026 via VC/OAVM.

Notice Of 31St Annual General Meeting Of The Company For The F.Y 2025-2026 19 Aug

FY26 annual report filed; 31st AGM on September 11, 2026 via VC/OAVM.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2018 Sep 2018 Jun 2019 Sep 2019
Sales + 12 9 7 12
Expenses + 14 9 10 12
Operating Profit -2 0 -3 0
OPM % -15.23% 2.04% -41.75% -3.28%
Other Income + 0 0 0 1
Interest 1 1 0 0
Depreciation 1 1 1 1
Profit before tax -4 -1 -4 -1
Tax % -1.12% 4.1% -42.59% 7.27%
Net Profit + -4 -1 -2 -1
EPS in Rs -1 -1 -1 -2
Raw PDF — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Sales + 129 175 185 97 85 65 46 44 42
Expenses + 110 153 162 114 85 71 81 57 41
Operating Profit 19 22 23 -18 1 -6 -35 -13 1
OPM % 15.0% 13.0% 12.0% -18.0% 0.6% -9.0% -77.0% -30.0% 2.9%
Other Income + 1 3 2 43 2 1 31 1 -22
Interest 8 12 13 13 13 11 7 2 0
Depreciation 6 8 9 6 5 4 4 3 3
Profit before tax 5 5 2 6 -15 -20 -15 -17 -24
Tax % 64.0% 27.0% 42.0% -2.0% -1.0% -4.0% 15.0% 6.0% 0.0%
Net Profit + 2 4 1 6 -15 -19 -17 -18 -24
EPS in Rs 1 2 1 3 -8 -10 -7 -8 -105
Dividend Payout % 0.0% 28.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Reserves 45 49 50 53 39 24 14 -5 49
Borrowings + 85 100 108 69 80 82 47 46 3
Other Liabilities + 70 93 59 59 54 53 54 54 17
Total Liabilities 219 261 236 200 193 178 138 119 71
Fixed Assets + 76 73 69 55 53 49 45 37 35
CWIP 0 0 0 0 0 0 0 0 0
Investments 0 0 0 17 17 17 0 0 0
Other Assets + 143 188 167 128 123 113 93 82 36
Total Assets 219 261 236 200 193 178 138 119 71
Equity Capital 18 19 19 19 19 19 24 24 2

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Cash from Operating Activity + 29 37 2 11 1 -1 -7 -2 -34
Cash from Investing Activity + -38 -6 -7 60 0 -5 38 15 33
Cash from Financing Activity + -1 -12 -13 -71 -1 6 -31 -14 7
Net Cash Flow -9 19 -18 0 0 0 0 0 6
CFO/OP 161 167 9 -73 175 16 20 14 -2,812
Free Cash Flow -1 34 0 44 -1 -1 40 3 -36

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 88.73% → 75.0%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 11.27% 11.57% 11.7% 11.71% 11.7% 11.7% 16.47% 15.66% 15.66% 15.66% 15.66% 15.66%
Promoters 88.73% 88.42% 88.29% 88.29% 88.29% 88.29% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 8.53% 9.34% 9.34% 9.34% 9.34% 9.34%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bafna Pharmaceuticals Ltd (this stock) 842 — 1.65 -6.18%
Gaudium Ivf N Women H L 837 36.2 5.55 24.7%
Kilitch Drugs India Ltd 786 26.2 2.81 10.6%
Wanbury Limited 784 18.2 12.38 76.5%
Health X Platform Limited 908 510.0 1.42 0.29%
Shree Ganesh Remedies Ltd 946 61.2 5.8 10.8%
Zim Laboratories Limited 716 194.0 2.42 1.59%

Which Mutual Funds Hold Bafna Pharmaceuticals Ltd?

Frequently Asked Questions about Bafna Pharmaceuticals Ltd

Community Sentiment

What are other investors saying about Bafna Pharmaceuticals Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.